Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)

The type 2 diabetes (T2D) therapy market will expand through 2034, supported by polypharmacy and the growing use of effective branded therapies offering nonglycemic benefits. Although the loss of exclusivity of several key T2D brands (e.g., DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 RA products) will exert downward pressure on market sales, the adoption of Eli Lilly’s retatrutide (a first-in-class triple agonist) and orforglipron (an oral nonpeptide GLP-1 RA), along with other late-phase emerging therapies, will offset these declines and support the T2D market throughout the forecast period. Significant unmet need remains for disease-modifying therapies that improve long-term patient outcomes and reduce the lifelong management burden faced by T2D patients.

QUESTIONS ANSWERED

• What are the drivers and constraints in the T2D therapy market, and how will the market evolve over the forecast period?
• How has the increasing use of Eli Lilly’s tirzepatide (Mounjaro) affected the prescribing of other GLP-1 RA products, such as Eli Lilly’s dulaglutide (Trulicity) and Novo Nordisk’s SC semaglutide (Ozempic), in the G7 markets?
• What impact will the launch of Novo Nordisk’s insulin icodec (Awiqli) have on daily basal insulins and the overall use of insulin analogues?
• How will the launch of nonbranded therapies affect the G7 T2D market?
• What do key opinion leaders think about late-phase emerging therapies such as Eli Lilly’s retatrutide and Novo Nordisk’s CagriSema?

CONTENT HIGHLIGHTS

• Geography: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
• Primary research: Country-specific interviews with thought-leading endocrinologists and diabetologists. Survey data collected for this and other Clarivate research.
• Epidemiology: Prevalence of T2D by country with population-specific diagnosed and drug-treated rates.
• Forecast: 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2034, segmented by brands / generics.
• Drug treatments: Coverage of key current and late-phase emerging therapies.

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.